A newly identified signaling pathway that stimulates glucose uptake in brown fat cells might be useful for treating type 2 diabetes and obesity, according to a study in The Journal of Cell Biology.
When the body encounters cold temperatures, the sympathetic nervous system activates adrenoceptors on the surface of brown fat cells to stimulate glucose uptake from the bloodstream. Brown fat cells then use this glucose as a fuel source to generate body heat. Glucose uptake also can be induced by insulin. However, although insulin-stimulated glucose-uptake is well understood, the mechanisms involved in the adrenoceptor-dependent process have been unclear.
Now, researchers in Sweden reveal that the mTORC2 signaling pathway is the key regulator of adrenoreceptor-stimulated glucose uptake in brown fat tissue in mice. The pathway, which involves a protein kinase called mTOR, stimulates the transport of a glucose-importing protein called GLUT1 to the surface of brown fat cells.
"One of the most interesting characteristics of this newly discovered signal pathway is that it differs from the signal pathway triggered by insulin," says senior author Tore Bengtsson from the Department of Molecular Biosciences, Wenner-Gren Institute, Stockholm University. "This means that the signal pathway in brown fat can most likely be activated even in patients with type 2 diabetes, where insulin signaling is impaired."
In addition to being an effective tool for controlling blood sugar levels in type 2 diabetes patients, these findings suggest that stimulating the mTORC2 pathway to take advantage of the energy-burning power of brown fat might be effective as a weight loss therapy.
Olsen, J.M., et al. 2014. J. Cell Biol. doi:10.1083/jcb.201403080
About The Journal of Cell Biology
The Journal of Cell Biology (JCB) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JCB content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works, and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit http://www.
Research reported in the press release was supported by the Australian Research Council, Australian National Health and Medical Research Council (NHMRC), Swedish Research Council, Novonordiskfonden, Stiftelsen Svenska Diabetesförbundets Forskningsfond, the Magnus Bergvall foundation, and the Carl Tryggers foundation.